SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a...

Full description

Saved in:
Bibliographic Details
Main Authors BLUM, CHARLES, A, NG, PUI, YEE, SZCZEPANKIEWICZ, BRUCE G, PERNI, ROBERT, B, DISCH, JEREMY S, WHITE, BRIAN H, CASAUBON, REBECCA, FOX, RYAN, MICHAEL, OALMANN, CHRISTOPHER, KOPPETSCH, KARSTEN, MILLER, WILLIAM, HENRY, CALDWELL, RICHARD DANA
Format Patent
LanguageEnglish
French
Published 11.08.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. La présente invention concerne de nouveaux composés d'urée pontés substitués, des analogues apparentés correspondants, des compositions pharmaceutiques et des méthodes d'utilisation correspondantes. Les composés modulateurs de la sirtuine peuvent être utilisés pour augmenter la durée de vie d'une cellule et à traiter et/ou pour prévenir un large éventail de maladies et de troubles, notamment, mais non exclusivement, les maladies et troubles associés au vieillissement ou au stress, le diabète, l'obésité, des maladies neurodégénératives, les maladies cardiovasculaires, les troubles de la coagulation sanguine, les inflammations, le cancer et/ou les bouffées vasomotrices, ainsi que des maladies ou troubles susceptibles d'êtres améliorés par une augmentation de l'activité mitochondriale. L'invention concerne également des compositions comprenant un composé modulateur de la sirtuine associé à un autre agent thérapeutique.
Bibliography:Application Number: WO2015US61501